# Phase 2/3 cancer trials recruiting: 154 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 154 trials in phase 2/3 for cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2/3 cancer trials: 154 rows for $7.70, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2-3/neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 154
- Recruiting or not yet: 154
- Read on: November 19, 2026

## Trials

The 25 newest of 154, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07935759 | Efficacy and Safety Exploration of Short Course Radiotherapy Followed by Surufatinib and Toripalimab in Neoadjuvant Treatment of Locally... | The First Hospital of Jilin University | Phase 2/3 | Recruiting | Rectal Cancer | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935759) |
| October 22, 2026 | NCT07888075 | Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or... | AVEO Pharmaceuticals, Inc. | Phase 2/3 | Not yet recruiting | Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC), Metastatic Non-small Cell... | 950 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888075) |
| October 1, 2026 | NCT07852195 | Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer | ECOG-ACRIN Cancer Research Group | Phase 2/3 | Not yet recruiting | Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | 432 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07852195) |
| September 21, 2026 | NCT07831824 | Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW \[Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic... | Lantheus Medical Imaging | Phase 2/3 | Recruiting | Prostate Cancer | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07831824) |
| August 12, 2026 | NCT07761429 | A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP) | Shandong New Time Pharmaceutical Co., LTD | Phase 2/3 | Recruiting | Cancer of Unknown Primary Site | 402 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761429) |
| August 10, 2026 | NCT07756008 | Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer | Tianjin Medical University Second Hospital | Phase 2/3 | Not yet recruiting | Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer, Bladder Cancer | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756008) |
| July 30, 2026 | NCT07736495 | Protective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis | Ain Shams University | Phase 2/3 | Recruiting | Colorectal Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07736495) |
| June 18, 2026 | NCT07656376 | Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With... | Jiangxi Kvvit Pharmaceutical Co., Ltd. | Phase 2/3 | Not yet recruiting | Pancreatic Cancer, Pancreatic Carcinoma | 465 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07656376) |
| June 9, 2026 | NCT07636486 | Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies | Nanfang Hospital, Southern Medical University | Phase 2/3 | Not yet recruiting | Luspatercept, Epoetin, Poor Erythroid Engraftment, Hematological Malignancies | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636486) |
| May 27, 2026 | NCT07608224 | HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC | West China Hospital | Phase 2/3 | Not yet recruiting | Urinary Bladder Neoplasms | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07608224) |
| May 22, 2026 | NCT07603349 | Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma | Nanfang Hospital, Southern Medical University | Phase 2/3 | Not yet recruiting | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 405 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07603349) |
| May 13, 2026 | NCT07585279 | A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer | Hebei Medical University Fourth Hospital | Phase 2/3 | Not yet recruiting | Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan, Second-Line | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07585279) |
| May 7, 2026 | NCT07573956 | Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies | All India Institute of Medical Sciences | Phase 2/3 | Recruiting | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | 369 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07573956) |
| April 24, 2026 | NCT07550205 | Tiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian Cancer | Shanghai Municipal Hospital of Traditional Chinese Medicine | Phase 2/3 | Not yet recruiting | Ovarian Neoplasms Malignant, Sleep Initiation and Maintenance Disorders, Medicine, Chinese Traditional, Chinese Herbal... | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07550205) |
| April 22, 2026 | NCT07544056 | A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer | BeBetter Med Inc | Phase 2/3 | Recruiting | Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer | 446 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07544056) |
| April 21, 2026 | NCT07542288 | Comparison of the Therapeutic Effects of Methylprednisolone and Dexamethasone on Peritumoral Edema During Radiotherapy for Brain Metastases: | The Second Affiliated Hospital of Hainan Medical University | Phase 2/3 | Not yet recruiting | Brain Metastases From Solid Tumors | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07542288) |
| April 20, 2026 | NCT07539779 | Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis | Nanfang Hospital, Southern Medical University | Phase 2/3 | Not yet recruiting | Luspatercept, Poor Erythroid Engraftment, Hematological Malignancies, Myelofibrosis (MF) | 196 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07539779) |
| April 17, 2026 | NCT07537998 | Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center... | Sponsor not shown (see the record) | Phase 2/3 | Recruiting | Low Anterior Resection Syndrome, Rectal Cancer | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07537998) |
| April 14, 2026 | NCT07528495 | A Trial Evaluating Omission of Radiotherapy to Regional Lymphatic's | All India Institute of Medical Sciences | Phase 2/3 | Recruiting | Head and Neck Cancer | 396 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07528495) |
| April 3, 2026 | NCT07509398 | FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer | Shanghai 10th People's Hospital | Phase 2/3 | Not yet recruiting | Unresectable Colorectal Cancer, Colorectal Cancer (Locally Advanced or Metastatic) | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509398) |
| April 1, 2026 | NCT07505472 | Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent... | The First Hospital of Jilin University | Phase 2/3 | Recruiting | Rectal Cancer | 212 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07505472) |
| March 17, 2026 | NCT07476443 | Renoprotective Role of Vitamin C and Coenzyme Q10 in Nephrotoxicity | Ain Shams University | Phase 2/3 | Not yet recruiting | Nephrotoxicity | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07476443) |
| March 16, 2026 | NCT07472153 | PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or... | N.N. Alexandrov National Cancer Centre | Phase 2/3 | Recruiting | Metastatic Cervical Cancer, Persistent Cervical Cancer, Recurrent Cervical Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07472153) |
| March 16, 2026 | NCT07472140 | PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian... | N.N. Alexandrov National Cancer Centre | Phase 2/3 | Recruiting | Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07472140) |
| March 11, 2026 | NCT07463313 | 6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 2/3 | Not yet recruiting | Thymoma and Thymic Carcinoma | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07463313) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Cancer Research UK | 8 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 6 |
| Fudan University | 5 |
| Monash University | 5 |
| Sun Yat-sen University | 4 |
| Nanfang Hospital, Southern Medical University | 3 |
| Second Affiliated Hospital of Guangzhou Medical University | 3 |
| [Shanghai Henlius Biotech](https://specstream.ai/data/clinical-trials/company/shanghai-henlius-biotech) | 3 |
| Turku University Hospital | 2 |
| NRG Oncology | 2 |
| Universitaire Ziekenhuizen KU Leuven | 2 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 2 |
| [RemeGen Co., Ltd.](https://specstream.ai/data/clinical-trials/company/remegen-co-ltd) | 2 |
| Affidea Nu-med Center of Oncological DIagnostics and Therapy | 2 |
| The First Hospital of Jilin University | 2 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 2 |
| M.D. Anderson Cancer Center | 2 |
| [Shanghai Pharmaceuticals Holding Co., Ltd](https://specstream.ai/data/clinical-trials/company/shanghai-pharmaceuticals-holding-co-ltd) | 2 |
| Sixth Affiliated Hospital, Sun Yat-sen University | 2 |
| West China Hospital | 2 |
| Ain Shams University | 2 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 2 |
| All India Institute of Medical Sciences | 2 |
| N.N. Alexandrov National Cancer Centre | 2 |
| ECOG-ACRIN Cancer Research Group | 2 |

## By country

| Country | Trials |
| --- | --- |
| China | 68 |
| United States | 37 |
| United Kingdom | 24 |
| Australia | 20 |
| Canada | 20 |
| France | 20 |
| Italy | 20 |
| Spain | 18 |
| Japan | 17 |
| Poland | 17 |
| South Korea | 16 |
| Belgium | 16 |
| Germany | 16 |
| Taiwan | 13 |
| Israel | 11 |
| Netherlands | 11 |
| Romania | 11 |
| Brazil | 10 |
| Austria | 10 |
| India | 10 |
| Turkey (Türkiye) | 9 |
| Switzerland | 8 |
| Argentina | 8 |
| Mexico | 7 |
| Sweden | 6 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Guatemalan restaurants in the United States](https://specstream.ai/data/businesses/guatemalan-restaurants/united-states)
- [Prenatal and perinatal care clinics in the United States](https://specstream.ai/data/businesses/prenatal-and-perinatal-care-clinics/united-states)
- [Apparel manufacturers in the United States](https://specstream.ai/data/businesses/apparel-manufacturers/united-states)
- [Employment agencies in the United States](https://specstream.ai/data/businesses/employment-agencies/united-states)
- [Motels in the United States](https://specstream.ai/data/businesses/motels/united-states)
- [Trinidadian restaurants in the United States](https://specstream.ai/data/businesses/trinidadian-restaurants/united-states)
